A prospective database for neuroendocrine cancer (NET) patients recommended for peptide radionuclide receptor therapy (PRRT): The New Zealand PRRT Database
Not Applicable
- Conditions
- euroendocrine cancerPeptide radionuclide receptor therapy (PRRT)Neuroendocrine cancerCancer - Neuroendocrine tumour (NET)
- Registration Number
- ACTRN12624000367549
- Lead Sponsor
- The University of Auckland
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Diagnosis of neuroendocrine neoplasm and recommended for PRRT treatment by the national NET MDM.
Exclusion Criteria
Diagnosis of neuroendocrine neoplasm but deemed unsuitable for PRRT treatment as determined by NET MDM.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease-specific survival[Mortality and cause of death from NZ National Collections. Outcome assessment anticipated biannually for 5-years following treatment.];PRRT treatment response[Radiographic response and clinical response, as indicated in patient medical records. 3 months after a patient's last cycle of PRRT.];Toxicity from PRRT[Using a customised list of toxicities of interest, these will be collected from patient medical records. All relevant toxicities will be captured that occur from the start of treatment to three months following end of treatment.]
- Secondary Outcome Measures
Name Time Method